Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Up 43.2% in November

Athira Pharma, Inc. (NASDAQ:ATHA) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 2,220,000 shares, a growth of 43.2% from the October 31st total of 1,550,000 shares. Approximately 6.2% of the shares of the company are short sold. Based on an average daily trading volume, of 5,150,000 shares, the short-interest ratio is presently 0.4 days.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ATHA. GSA Capital Partners LLP boosted its holdings in shares of Athira Pharma by 909.8% in the third quarter. GSA Capital Partners LLP now owns 397,111 shares of the company’s stock worth $177,000 after acquiring an additional 357,787 shares during the period. Bristlecone Advisors LLC grew its position in shares of Athira Pharma by 295.6% during the 3rd quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock valued at $151,000 after purchasing an additional 252,200 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Athira Pharma by 84.1% in the first quarter. Jacobs Levy Equity Management Inc. now owns 497,475 shares of the company’s stock worth $1,363,000 after purchasing an additional 227,278 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Athira Pharma by 25.5% in the second quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock worth $1,458,000 after purchasing an additional 111,759 shares during the period. Finally, Invst LLC purchased a new stake in shares of Athira Pharma in the second quarter worth $68,000. 57.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ATHA has been the topic of a number of recent analyst reports. Mizuho lowered Athira Pharma from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $5.00 to $0.50 in a report on Thursday, September 19th. BTIG Research cut Athira Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 4th. JMP Securities lowered shares of Athira Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 4th. Finally, Rodman & Renshaw lowered shares of Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th.

Athira Pharma Price Performance

Shares of ATHA opened at $0.66 on Friday. The firm has a market cap of $25.34 million, a PE ratio of -0.23 and a beta of 2.82. Athira Pharma has a 1 year low of $0.41 and a 1 year high of $4.30. The stock’s fifty day moving average price is $0.54 and its two-hundred day moving average price is $1.85.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.05. Sell-side analysts anticipate that Athira Pharma will post -2.35 earnings per share for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.